A test for anti-TNF non-responders? Few alternative RA therapies available
This article was originally published in Scrip
Tumor necrosis factor (TNF) inhibitors, such as Amgen's Enbrel (etanercept) and AbbVie's Humira (adalimumab), are the biologics of choice to treat rheumatoid arthritis (RA) patients. But many people with the debilitating autoimmune disease don't respond to anti-TNF therapies, so what if you could identify patients early on who won't respond to those biologics?